EA199900912A1 - Фармацевтические средства - Google Patents

Фармацевтические средства

Info

Publication number
EA199900912A1
EA199900912A1 EA199900912A EA199900912A EA199900912A1 EA 199900912 A1 EA199900912 A1 EA 199900912A1 EA 199900912 A EA199900912 A EA 199900912A EA 199900912 A EA199900912 A EA 199900912A EA 199900912 A1 EA199900912 A1 EA 199900912A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutical agents
selective
antagonists
glur5 receptor
pain
Prior art date
Application number
EA199900912A
Other languages
English (en)
Inventor
Дэвид Бликман
Дэвид Р. Хелтон
Дэвид Лодж
Смрити Ийенгар
Пол Л. Орнстейн
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA199900912A1 publication Critical patent/EA199900912A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Заявлены антагонисты, которые являются селективными в отношении GluR5 рецептора, полезные для лечения боли. Также раскрыты новые производные декагидроизохинолина, являющиеся селективными антагонистами рецептора GluR5.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA199900912A 1997-04-07 1998-04-06 Фармацевтические средства EA199900912A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4279597P 1997-04-07 1997-04-07
PCT/US1998/006905 WO1998045270A1 (en) 1997-04-07 1998-04-06 Pharmacological agents

Publications (1)

Publication Number Publication Date
EA199900912A1 true EA199900912A1 (ru) 2000-04-24

Family

ID=21923795

Family Applications (1)

Application Number Title Priority Date Filing Date
EA199900912A EA199900912A1 (ru) 1997-04-07 1998-04-06 Фармацевтические средства

Country Status (17)

Country Link
US (1) US6242462B1 (ru)
EP (1) EP0980358A4 (ru)
JP (1) JP2001521505A (ru)
KR (1) KR20010006075A (ru)
CN (1) CN1259126A (ru)
AU (1) AU734657B2 (ru)
BR (1) BR9809071A (ru)
CA (1) CA2285192A1 (ru)
EA (1) EA199900912A1 (ru)
HU (1) HUP0002030A3 (ru)
ID (1) ID23013A (ru)
IL (1) IL132086A0 (ru)
NO (1) NO994850D0 (ru)
NZ (1) NZ337827A (ru)
PL (1) PL336068A1 (ru)
TR (1) TR199902449T2 (ru)
WO (1) WO1998045270A1 (ru)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6486175B1 (en) 1999-07-06 2002-11-26 Eli Lilly And Company Diester prodrugs of a decahydroisoquinoline-3-carboxylic acid
CN1230174C (zh) * 1999-07-06 2005-12-07 伊莱利利公司 治疗偏头痛的选择性iGluR5受体拮抗剂
EP1257545A1 (en) 1999-12-22 2002-11-20 Eli Lilly And Company SELECTIVE iGLUR 5? RECEPTOR ANTAGONISTS
WO2002053556A2 (en) 2001-01-05 2002-07-11 Eli Lilly And Company Pyrrolidinylmethyl substituted decahydroisoquinolines as excitatory amino acid receptor antagonists
WO2002053139A2 (en) * 2001-01-05 2002-07-11 Eli Lilly And Company Excitatory amino acid receptor antagonist and 5-ht1f agonist combination: a method for the treatment of neurological disorders
US7205313B2 (en) 2001-01-05 2007-04-17 Eli Lilly And Company Excitatory amino acid receptor antagonists
EP1351951A2 (en) 2001-01-05 2003-10-15 Eli Lilly And Company Pyrrolidinylmethyl- and piperidinyl substituted decahydroisoquinolines as excitatory amino acid receptor antagonists
US6924294B2 (en) 2001-01-05 2005-08-02 Eli Lilly And Company Excitatory amino acid receptor antagonists
MXPA03005982A (es) * 2001-01-05 2003-09-10 Lilly Co Eli Antagonistas de receptores de aminoacidos excitadores.
WO2002058691A1 (en) * 2001-01-23 2002-08-01 Neurosearch A/S Use of non-competitive and selective glur5 antagonists as glutamate receptor modulating compounds
ES2398225T3 (es) 2002-04-26 2013-03-14 Eli Lilly And Company Derivados de éster de un ácido DECAHIDROISOQUINOLIN-3-CARBOXÍLICO como analgésicos
US20050101597A1 (en) * 2003-07-10 2005-05-12 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitior and a non-NMDA glutamate modulator for the treatment of central nervous system damage
JP4964593B2 (ja) * 2003-09-25 2012-07-04 セノメド バイオサイエンシーズ，エルエルシー 神経学的病状の治療用のテトラヒドロインドロン誘導体
US20050107439A1 (en) * 2003-11-10 2005-05-19 Helton David R. Composition and method for treating emesis
EP2578216A1 (en) 2006-11-22 2013-04-10 Seaside Therapeutics, Inc. Methods of treating fragile x syndrome
WO2008088820A2 (en) 2007-01-16 2008-07-24 The Johns Hopkins University Glutamate receptor antagonists and methods of use
WO2009062134A1 (en) * 2007-11-09 2009-05-14 Cenomed Biosciences, Llc Treatment of post-traumatic stress disorder with tetrahydroindolone arylpiperazine compounds
US20090264443A1 (en) * 2008-04-18 2009-10-22 David Helton Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds
WO2011109398A2 (en) 2010-03-02 2011-09-09 President And Fellows Of Harvard College Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
US20110294879A1 (en) 2010-05-28 2011-12-01 Xenoport, Inc. Method of treatment of fragile x syndrome, down's syndrome, autism and related disorders
WO2012009646A1 (en) 2010-07-15 2012-01-19 Xenoport, Inc. Methods of treating fragile x syndrome, down's syndrome, autism and related disorders
KR101746944B1 (ko) * 2015-09-23 2017-06-14 주식회사 포스코 도장 선영성이 우수한 도금강판의 제조방법 및 이에 의해 제조된 도금강판

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284957A (en) 1992-09-03 1994-02-08 Eli Lilly And Company Excitatory amino acid receptor antagonists
US5446051A (en) * 1994-05-31 1995-08-29 Eli Lilly And Company Aryl-spaced decahydroisoquinoline-3-carboxylic acids as excitatory amino acid receptor antagonists
JPH11501619A (ja) * 1995-02-15 1999-02-09 ベアーズデン バイオ，インコーポレイテッド アルキルカルボキシアミノ酸−カイネートレセプターのモジュレーター

Also Published As

Publication number Publication date
CN1259126A (zh) 2000-07-05
US6242462B1 (en) 2001-06-05
WO1998045270A1 (en) 1998-10-15
HUP0002030A2 (hu) 2001-04-28
CA2285192A1 (en) 1998-10-15
EP0980358A1 (en) 2000-02-23
HUP0002030A3 (en) 2002-01-28
NO994850L (no) 1999-10-05
ID23013A (id) 1999-12-30
TR199902449T2 (xx) 2000-07-21
PL336068A1 (en) 2000-06-05
IL132086A0 (en) 2001-03-19
AU734657B2 (en) 2001-06-21
NO994850D0 (no) 1999-10-05
KR20010006075A (ko) 2001-01-15
EP0980358A4 (en) 2001-02-07
AU6955598A (en) 1998-10-30
NZ337827A (en) 2000-12-22
BR9809071A (pt) 2000-08-01
JP2001521505A (ja) 2001-11-06

Similar Documents

Publication Publication Date Title
EA199900912A1 (ru) Фармацевтические средства
DK0918774T3 (da) Androgenreceptormodulatorforbindelser og fremgangsmåder
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
PT800519E (pt) Compostos moduladores de receptores de esteroides e metodos
FI952064A0 (fi) Takykiniinireseptoriantagonisteja, joilla ei ole peptidyylirakennetta
DE69728585D1 (de) Mittel gegen Juckreiz
BRPI0010891B1 (pt) geração de microespuma terapêutica.
ATE304530T1 (de) Substituierte 1,5-dihydropyrrol-2-on-derivate wirksam als nmda-rezeptor-antagonisten für die behandlung von schmerzzuständen
ATE288747T1 (de) Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren
IT1319240B1 (it) Procedimento per la oligomerizzazione selettiva dell'etilene.
TR199700956T1 (xx) Indazolkarboksamidler.
IT1302243B1 (it) Sintesi dell'1,1,1,3,3-pentafluoropropano.
ATE139226T1 (de) Aminosulfonylharnstoff-acat-inhibitoren
DK1140931T3 (da) 5HT1-antagonister til antidepressiv behandling
ES2189940T3 (es) Antagonista de receptor at1 para la estimulacion de la apoptosis.
EA200101106A1 (ru) Фармацевтический комплекс
ATE282416T1 (de) Die verwendung von nk-1 rezeptor antagonisten für die behandlung von substanz-verwendung störungen
DK412286A (da) 4-acylaminobenzamid-derivater, fremgangsmaade til fremstilling heraf samt mellemprodukter til brug ved fremgangsmaaden
FR2783521B1 (fr) Derives de n-(arginyl) benzenesulfonamide, leur preparation et leur application en therapeutique
BR9909878A (pt) 10-canfosulfonato de paroxetina para tratamento de distúrbios do sistema nervoso central
DE69925008D1 (de) Protein, welches die aktivität von d1-ähnlichen dopamin rezeptoren modifiziert
ES1041026Y (es) Vibrador terapeutico.
IT8919443A0 (it) Agenti modificanti di asfalti, procedimenti per la modificazione di asfalti modificati.
DK1200402T3 (da) Substituerede 1,5-dihydropyrrol-2-on-derivater med virkning som NMDA-receptorantagonister til behandling af smertetilstande